Skip to Content

Cenegermin use while Breastfeeding

Drugs containing Cenegermin: Oxervate

Medically reviewed by Drugs.com. Last updated on Jan 17, 2021.

Cenegermin Levels and Effects while Breastfeeding

Summary of Use during Lactation

Because cenegermin is a large protein molecule with a molecular weight of 13,266, and absorption from the eye is limited, the amount in milk is likely to be very low and oral absorption by the infant is unlikely because it is probably destroyed in the infant's gastrointestinal tract. To substantially diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue. Ophthalmic cenegermin is not expected to cause any adverse effects in breastfed infants.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Cenegermin

CAS Registry Number

1772578-74-1

Drug Class

  • Breast Feeding
  • Lactation
  • Nerve Growth Factors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

More about cenegermin ophthalmic

Consumer resources

Other brands
Oxervate

Professional resources

Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.